WO1999033980A3 - Members of tnf and tnfr families - Google Patents
Members of tnf and tnfr families Download PDFInfo
- Publication number
- WO1999033980A3 WO1999033980A3 PCT/US1998/027474 US9827474W WO9933980A3 WO 1999033980 A3 WO1999033980 A3 WO 1999033980A3 US 9827474 W US9827474 W US 9827474W WO 9933980 A3 WO9933980 A3 WO 9933980A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tnf
- members
- proteins
- tnfr
- tnfr families
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU20934/99A AU2093499A (en) | 1997-12-30 | 1998-12-22 | Members of tnf and tnfr families |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6895997P | 1997-12-30 | 1997-12-30 | |
| US60/068,959 | 1997-12-30 | ||
| US21227098A | 1998-12-16 | 1998-12-16 | |
| US09/212,270 | 1998-12-16 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| WO1999033980A2 WO1999033980A2 (en) | 1999-07-08 |
| WO1999033980A9 WO1999033980A9 (en) | 1999-10-14 |
| WO1999033980A3 true WO1999033980A3 (en) | 1999-11-18 |
Family
ID=26749548
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US1998/027474 Ceased WO1999033980A2 (en) | 1997-12-30 | 1998-12-22 | Members of tnf and tnfr families |
Country Status (2)
| Country | Link |
|---|---|
| AU (1) | AU2093499A (en) |
| WO (1) | WO1999033980A2 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9982302B2 (en) | 2011-02-28 | 2018-05-29 | Genentech, Inc. | Biological markers and methods for predicting response to B-cell antagonists |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7217788B2 (en) | 1996-03-14 | 2007-05-15 | Human Genome Sciences, Inc. | Human tumor necrosis factor delta polypeptides |
| US6541224B2 (en) | 1996-03-14 | 2003-04-01 | Human Genome Sciences, Inc. | Tumor necrosis factor delta polypeptides |
| US6689579B1 (en) | 1996-10-25 | 2004-02-10 | Human Genome Sciences, Inc. | Polynucleotides encoding neutrokine-α |
| US6812327B1 (en) | 1996-10-25 | 2004-11-02 | Human Genome Sciences, Inc. | Neutrokine-alpha polypeptides |
| US7285267B2 (en) | 1997-01-14 | 2007-10-23 | Human Genome Sciences, Inc. | Tumor necrosis factor receptors 6α & 6β |
| DE69837996T2 (en) | 1997-01-14 | 2008-02-28 | Human Genome Sciences, Inc. | TUMOR NECROSE FACTOR RECEPTORS 6 ALPHA & 6 BETA |
| DE69837606T2 (en) | 1997-09-12 | 2008-02-14 | Biogen Idec Ma Inc., Cambridge | CYSTEIN RICH RECEPTORS TRAIN |
| US6297367B1 (en) * | 1997-12-30 | 2001-10-02 | Chiron Corporation | Polynucleotide encoding TNFL1 |
| CA2318743A1 (en) * | 1998-01-27 | 1999-07-29 | Millennium Pharmaceuticals, Inc. | Novel molecules of the tnf receptor superfamily and uses therefor |
| US20030095967A1 (en) | 1999-01-25 | 2003-05-22 | Mackay Fabienne | BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders |
| CA2360062A1 (en) | 1999-01-25 | 2000-07-27 | Biogen, Inc. | Baff, inhibitors thereof and their use in the modulation of b-cell response |
| US6475986B1 (en) | 1999-02-02 | 2002-11-05 | Research Development Foundation | Uses of THANK, a TNF homologue that activates apoptosis |
| AU2574200A (en) * | 1999-02-19 | 2000-09-04 | Toshio Kitamura | Novel tnf receptor-like proteins |
| NZ513290A (en) * | 1999-02-23 | 2004-05-28 | Human Genome Sciences Inc | Neutrokine-alpha and neutrokine-alpha splice variant |
| US20030022233A1 (en) | 1999-04-30 | 2003-01-30 | Raymond G. Goodwin | Methods of use of the taci/taci-l interaction |
| SK288603B6 (en) | 1999-08-17 | 2018-10-01 | Biogen Ma Inc. | Polypeptide and antibody binding to polypeptide |
| UA74798C2 (en) | 1999-10-06 | 2006-02-15 | Байоджен Айдек Ма Інк. | Method for treating cancer in mammals using polypeptide interfering with interaction between april and its receptors |
| AU2048501A (en) | 2000-02-16 | 2001-08-27 | Genentech Inc. | Uses of agonists and antagonists to modulate activity of tnf-related molecules |
| PL357939A1 (en) | 2000-04-11 | 2004-08-09 | Genentech, Inc. | Multivalent antibodies and uses therefor |
| AU2001263114A1 (en) | 2000-05-12 | 2001-11-26 | Amgen Inc | Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci |
| EP2281843B1 (en) | 2000-06-16 | 2016-10-12 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to BLyS |
| US7220840B2 (en) | 2000-06-16 | 2007-05-22 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to B lymphocyte stimulator protein |
| WO2002009755A2 (en) | 2000-07-27 | 2002-02-07 | Genentech, Inc. | Apo-2l receptor agonist and cpt-11 synergism |
| AU2001288301A1 (en) | 2000-08-18 | 2002-03-04 | Human Genome Sciences, Inc. | Binding polypeptides and methods based thereon |
| UA83458C2 (en) | 2000-09-18 | 2008-07-25 | Байоджен Айдек Ма Інк. | The isolated polypeptide baff-r (the receptor of the factor of activation of b-cells of the family tnf) |
| US7019012B2 (en) | 2000-12-20 | 2006-03-28 | Boehringer Ingelheim International Pharma Gmbh & Co. Kg | Quinazoline derivatives and pharmaceutical compositions containing them |
| AU2002311976A1 (en) | 2001-05-24 | 2002-12-03 | Human Genome Sciences, Inc. | Antibodies against tumor necrosis factor delta (april) |
| CA2451680C (en) | 2001-07-03 | 2011-04-19 | Genentech, Inc. | Human dr4 antibodies and uses thereof |
| DE10221018A1 (en) | 2002-05-11 | 2003-11-27 | Boehringer Ingelheim Pharma | Use of inhibitors of EGFR-mediated signal transduction for the treatment of benign prostatic hyperplasia (BPH) / prostatic hypertrophy |
| CA2520097C (en) | 2003-03-28 | 2014-10-07 | Biogen Idec Ma Inc. | Truncated baff receptors |
| PL1631313T3 (en) | 2003-06-05 | 2015-08-31 | Genentech Inc | Combination therapy for b cell disorders |
| AU2004315198A1 (en) | 2004-01-29 | 2005-08-18 | Genentech, Inc. | Variants of the extracellular domain of BCMA and uses thereof |
| US20050186577A1 (en) | 2004-02-20 | 2005-08-25 | Yixin Wang | Breast cancer prognostics |
| CN101014245A (en) | 2004-08-03 | 2007-08-08 | 比奥根艾迪克Ma公司 | Taj in neuronal function |
| SG165344A1 (en) | 2004-10-05 | 2010-10-28 | Genentech Inc | Method for treating vasculitis |
| EP1836224A1 (en) | 2004-12-23 | 2007-09-26 | Laboratoires Serono S.A. | Bcma polypeptides and uses thereof |
| US9168286B2 (en) | 2005-10-13 | 2015-10-27 | Human Genome Sciences, Inc. | Methods and compositions for use in treatment of patients with autoantibody positive disease |
| EP3173084B1 (en) | 2005-11-11 | 2019-10-23 | Boehringer Ingelheim International GmbH | Quinazoline derivatives for the treatment of cancer diseases |
| MY149159A (en) | 2005-11-15 | 2013-07-31 | Hoffmann La Roche | Method for treating joint damage |
| WO2007062090A2 (en) | 2005-11-23 | 2007-05-31 | Genentech, Inc. | Methods and compositions related to b cell assays |
| WO2007123765A2 (en) | 2006-03-31 | 2007-11-01 | Human Genome Sciences Inc. | Neutrokine-alpha and neutrokine-alpha splice variant |
| KR20090074202A (en) | 2006-09-18 | 2009-07-06 | 베링거 인겔하임 인터내셔날 게엠베하 | How to treat cancer with EVFR mutation |
| WO2010075249A2 (en) | 2008-12-22 | 2010-07-01 | Genentech, Inc. | A method for treating rheumatoid arthritis with b-cell antagonists |
| EP2451445B1 (en) | 2009-07-06 | 2019-04-03 | Boehringer Ingelheim International GmbH | Process for drying of bibw2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient |
| MX2012002766A (en) | 2009-09-03 | 2012-04-02 | Genentech Inc | Methods for treating, diagnosing, and monitoring rheumatoid arthritis. |
| WO2011109280A1 (en) | 2010-03-05 | 2011-09-09 | Lerner Research Institute | Methods and compositions to treat immune-mediated disorders |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997033902A1 (en) * | 1996-03-14 | 1997-09-18 | Human Genome Sciences, Inc. | Human tumor necrosis factor delta and epsilon |
| WO1998018921A1 (en) * | 1996-10-25 | 1998-05-07 | Human Genome Sciences, Inc. | NEUTROKINE $g(a) |
| WO1998027114A2 (en) * | 1996-12-17 | 1998-06-25 | Schering Corporation | Mammalian cell surface antigens; related reagents |
| EP0869180A1 (en) * | 1997-04-02 | 1998-10-07 | Smithkline Beecham Corporation | A TNF homologue, TL5 |
| WO1998055621A1 (en) * | 1997-06-06 | 1998-12-10 | Regeneron Pharmaceuticals, Inc. | Ntn-2 member of tnf ligand family |
| WO1998055620A1 (en) * | 1997-06-06 | 1998-12-10 | Regeneron Pharmaceuticals, Inc. | Ntn-2 member of tnf ligand family |
| WO1999011791A2 (en) * | 1997-09-05 | 1999-03-11 | University Of Washington | Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents |
| WO1999012964A2 (en) * | 1997-09-12 | 1999-03-18 | Biogen, Inc. | Kay - a novel immune system protein |
-
1998
- 1998-12-22 WO PCT/US1998/027474 patent/WO1999033980A2/en not_active Ceased
- 1998-12-22 AU AU20934/99A patent/AU2093499A/en not_active Abandoned
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997033902A1 (en) * | 1996-03-14 | 1997-09-18 | Human Genome Sciences, Inc. | Human tumor necrosis factor delta and epsilon |
| WO1998018921A1 (en) * | 1996-10-25 | 1998-05-07 | Human Genome Sciences, Inc. | NEUTROKINE $g(a) |
| WO1998027114A2 (en) * | 1996-12-17 | 1998-06-25 | Schering Corporation | Mammalian cell surface antigens; related reagents |
| EP0869180A1 (en) * | 1997-04-02 | 1998-10-07 | Smithkline Beecham Corporation | A TNF homologue, TL5 |
| WO1998055621A1 (en) * | 1997-06-06 | 1998-12-10 | Regeneron Pharmaceuticals, Inc. | Ntn-2 member of tnf ligand family |
| WO1998055620A1 (en) * | 1997-06-06 | 1998-12-10 | Regeneron Pharmaceuticals, Inc. | Ntn-2 member of tnf ligand family |
| WO1999011791A2 (en) * | 1997-09-05 | 1999-03-11 | University Of Washington | Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents |
| WO1999012964A2 (en) * | 1997-09-12 | 1999-03-18 | Biogen, Inc. | Kay - a novel immune system protein |
Non-Patent Citations (4)
| Title |
|---|
| AGGARWAL B.B. AND NATARAJAN K.: "Tumor necrosis factor: developments during the last decade", EUROPEAN CYTOKINE NETWORK, vol. 7, no. 2, April 1996 (1996-04-01) - June 1996 (1996-06-01), pages 93 - 124, XP002094503 * |
| DATABASE EMBL NUCLEOTIDE SEQU 1 January 1900 (1900-01-01), XP002101204, Database accession no. AA682496 * |
| GRUSS H.-J. AND DOWER S.K.: "Tumor necrosis factor ligand superfamily: involvement in the pathology of malignant lymphomas", BLOOD, vol. 85, no. 12, 15 June 1995 (1995-06-15), pages 3378 - 3404, XP002094502 * |
| GRUSS H.-J.: "Molecular, structural, and biological characteristics of the tumor necrosis factor ligand superfamily", INTERNATIONAL JOURNAL OF CLINICAL AND LABORATORY RESEARCH, vol. 26, no. 3, 1996, pages 143 - 159, XP002094504 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9982302B2 (en) | 2011-02-28 | 2018-05-29 | Genentech, Inc. | Biological markers and methods for predicting response to B-cell antagonists |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2093499A (en) | 1999-07-19 |
| WO1999033980A9 (en) | 1999-10-14 |
| WO1999033980A2 (en) | 1999-07-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO1999033980A3 (en) | Members of tnf and tnfr families | |
| WO2000060079A3 (en) | New members of tnf and tnfr families | |
| Scanlon et al. | Cisplatin resistance in human cancers | |
| CA2063427A1 (en) | Rapid, versatile and simple system for expressing genes in eukaryotic cells | |
| Marshall | Less hype, more biology needed for gene therapy | |
| CA2005016A1 (en) | Dna fragment containing promoter region for human polypeptide chain elongation factor-1.alpha. and expression plasmid containing the dna fragment | |
| CA2228635A1 (en) | Mammalian apoptosis inhibitor protein gene family, primers, probes and detection methods | |
| NZ297537A (en) | method for changing the cell characteristics of the female reproductive tract | |
| GR3015015T3 (en) | Leukocyte poor red blood cell storage system. | |
| AU716500B2 (en) | Nucleic acid constructs for the cell cycle-regulated expression of genes, cells containing such constructs and their use for preparing drugs | |
| WO2004056868A3 (en) | Nf-hev compositions and methods of use | |
| DE68909958D1 (en) | Phenoxyacetic acid derivatives, their preparation, pharmaceutical compositions containing them and their use. | |
| IE830945L (en) | Process for obtaining permanently culturable animal and¹human cell lines | |
| Harris | DNA repair and resistance to chemotherapy | |
| EP0525917A3 (en) | Double-stranded rna correction of aberrant metabolic pathways associated with uncontrolled tumor cell and virus growth cycles | |
| AU3584993A (en) | Methods and compositions for neutralizing intracellular nucleic acid-binding protein biological activity in a cell, including methods and compositions useful to regulate gene function | |
| AU7437900A (en) | Cryopreserved amniotic human cells for future therapeutic, diagnostic, genetic and others uses | |
| AU3045189A (en) | Determination of genetic sex in ruminants using y-chromosome-specific polynucleotides | |
| IT1241123B (en) | HUMAN CELLS FOR THE HIGH EXPRESSION OF GENES INSERTED IN DNA EPISOMIAL RECOMBINANTS, THEIR PREPARATION AND THEIR USE | |
| Copeland et al. | Regional localization of three convertases, PC1 (Nec-1), PC2 (Nec-2), and furin (Fur), on mouse chromosomes | |
| Moore et al. | Malic dehydrogenases in sea urchin eggs | |
| Konstantinović et al. | Nuclear matrix from resting and concanavalin A-stimulated human lymphocytes | |
| Pool et al. | Zygote intrafallopian transfer with" donor rescue": a new option for severe male factor infertility | |
| MD1119G2 (en) | Method for female genitals inflammatory diseases treatment | |
| DE3853112D1 (en) | DNA molecules which encode placental bovine lactogen peptide and the pre-peptide and genetically transformed cells which contain these molecules. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AU CA JP |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| AK | Designated states |
Kind code of ref document: C2 Designated state(s): AU CA JP |
|
| AL | Designated countries for regional patents |
Kind code of ref document: C2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
| COP | Corrected version of pamphlet |
Free format text: PAGES 1/5-5/5, DRAWINGS, REPLACED BY NEW PAGES 1/9-9/9; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE |
|
| AK | Designated states |
Kind code of ref document: A3 Designated state(s): AU CA JP |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
| 122 | Ep: pct application non-entry in european phase |